Cargando…

Long-term immunogenicity of hepatitis B vaccine and impact of a booster dose on health care

Background: Accidental exposure to sharp instruments is an important problem for health care students. Thus, the aim of this study was to determine the rate of immunity in health care students 2 decades after national neonatal hepatitis B (HB) vaccination. Methods: All junior students attending medi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bijani, Behzad, Allami, Abbas, Jafari, Farzaneh, Hajmanoochehri, Fatemeh, Bijani, Soroush
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iran University of Medical Sciences 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662535/ https://www.ncbi.nlm.nih.gov/pubmed/31380310 http://dx.doi.org/10.34171/mjiri.33.20

Ejemplares similares

Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial
por: Zarehoseinzade, Elham, et al.
Publicado: (2021)

Long-Term Immunogenicity upon Pertussis Booster Vaccination in Young Adults and Children in Relation to Priming Vaccinations in Infancy
por: Versteegen, Pauline, et al.
Publicado: (2022)

Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up: Efficacy of HBV vaccine in those who lost HBsAg
por: Taheri, Hassan, et al.
Publicado: (2011)

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
por: Wroński, Jakub, et al.
Publicado: (2022)

Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination
por: Ramezani, Amitis, et al.
Publicado: (2014)

The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy
por: Coppola, Nicola, et al.
Publicado: (2015)

Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023)

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial
por: Omma, Ahmet, et al.
Publicado: (2022)

Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination
por: Terbsiri, Varalee, et al.
Publicado: (2023)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

The necessity of booster vaccination after neonatal hepatitis B vaccination
por: Lankarani, Kamran Bagheri
Publicado: (2011)

Predictive factors for anti-HBs status after 1 booster dose of hepatitis B vaccine
por: Lu, I-Cheng, et al.
Publicado: (2016)

Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters
por: Anoush, Mahdieh, et al.
Publicado: (2023)

2231. Long-Term Immunogenicity of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: An Extension of a Randomized Controlled Trial
por: Chaiwarith, Romanee, et al.
Publicado: (2018)

Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose
por: Perico, Luca, et al.
Publicado: (2023)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Response to Booster Doses of Hepatitis B Vaccine among Young Adults Who Had Received Neonatal Vaccination
por: Chan, Paul K. S., et al.
Publicado: (2014)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Modeling long-term persistence after 8 years of hepatitis B booster vaccination in 5- to 15-year-old children
por: Qiu, Yan, et al.
Publicado: (2022)

Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults
por: Cooper, Curtis, et al.
Publicado: (2011)

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years
por: Borja-Tabora, Charissa Fay Corazon, et al.
Publicado: (2020)

636. Immunogenicity, Safety and Tolerability of a Booster Dose of Clostridium difficile Vaccine and 4 Year Antibody Persistence
por: Remich, Shon A, et al.
Publicado: (2020)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Assessment of Bax and Bcl-2 Immunoexpression in Patients with Oral Lichen Planus and Oral Squamous Cell Carcinoma
por: Nafarzadeh, Shima, et al.
Publicado: (2013)

Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children
por: Mitra, Monjori, et al.
Publicado: (2015)

Long term Immunogenicity of Single Dose of Live Attenuated Hepatitis A Vaccine in Indian Children — Results of 15-Year Follow-up
por: Bhave, Sheila, et al.
Publicado: (2021)

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022)

Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination
por: Zhao, Yu-Liang, et al.
Publicado: (2019)

Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren
por: Kamoltham, Thavatchai, et al.
Publicado: (2011)

The Impact of an Educational Program Regarding Total Parenteral Nutrition on Infection Indicators in Neonates Admitted to the Neonatal Intensive Care Unit
por: Marofi, Maryam, et al.
Publicado: (2017)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
por: Lai, Kristi Tsz-Wan, et al.
Publicado: (2022)

Immunogenicity of two different hepatitis B vaccine schedules
por: Agladioglu, S. Y., et al.
Publicado: (2011)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

Adjuvant Effect of Bacille Calmette–Guérin on Hepatitis B Vaccine Immunogenicity in the Preterm and Term Newborn
por: Scheid, Annette, et al.
Publicado: (2018)

FNAC accuracy in diagnosis of thyroid neoplasms considering all diagnostic categories of the Bethesda reporting system: A single-institute experience
por: Hajmanoochehri, Fatemeh, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_18p1maienfm3mn7m71ccovth72